John Tucker

XyloCor Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease, has appointed John Tucker as President and Chief Executive Officer. 

With more than 20 years of leadership experience in biotechnology and life sciences, Tucker brings a strong track record in advancing clinical programs, building high-performing teams, and driving strategic growth. He succeeds the company’s interim leadership and will also join the Board of Directors.

Before joining XyloCor, Tucker served as Chief Executive Officer of scPharmaceuticals and previously held the CEO position at Alcresta Therapeutics. Throughout his career, he has played a key role in IPO execution, regulatory approvals, and the commercialization of innovative therapies.

Tucker also brings extensive experience in fundraising initiatives, strategic partnerships, and late-stage clinical development programs. His leadership is expected to support XyloCor’s mission to advance novel therapies addressing significant unmet needs in cardiovascular disease.